
FDA proposes setting a bar for weight-loss therapies; exposure to aircraft noise and heart function; Athira Pharma Inc. pays $4 million to settle false claims allegation – Morning Medical Update
Key Takeaways
- FDA's draft guidance recommends a minimum 5% weight loss for investigational obesity therapies to establish efficacy.
- Aircraft noise exposure is associated with stiffer heart muscles and increased risk of major cardiac events.
The top news stories in medicine today.
In a draft guidance released to the public for comment on Tuesday, the U.S. Food and Drug Administration (FDA) set out efficacy standards for investigational obesity therapies, recommending a minimum of 5% weight-loss for drug developers intent on establishing the efficacy of their investigational obesity candidates. Under the guidance, a drug candidate would be considered effective for long-term weight loss and management if it is able to demonstrate at least a 5% decrease in body weight compared to the control after one year of treatment.
A new study led by University College London (UCL) researchers and published in the
Athira Pharma Inc. has
Newsletter
Stay informed and empowered with Medical Economics enewsletter, delivering expert insights, financial strategies, practice management tips and technology trends — tailored for today’s physicians.



















